Regulation · Comment closed 30 July 2026
The FDA 503B decision: where compounded GLP-1s actually stand
The FDA's comment period on permanently excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list closed on 30 July 2026, and no final decision has been announced. Anyone telling you compounded GLP-1s are banned is ahead of the facts — and anyone telling you nothing is changing is behind them.
What has actually happened
On 30 April 2026 the FDA announced it had found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. The notice opened in the Federal Register on 1 May with a 60-day comment window, was extended by 30 days on 26 June after a request for more time, and closed on 30 July 2026. The agency has said it will consider the comments before making a final determination. As of this writing it has not made one.
The part that is widely misreported
These molecules were never on the 503B bulks list. The proposal keeps them off it rather than removing them from it, which sounds like a technicality and is not: a proposal to foreclose a pathway is a different legal act from one closing an open pathway, and it shapes what litigation over it can argue.
Second thing routinely conflated: 503B outsourcing facilities and 503A pharmacies are not the same, and this proposal is about 503B. Patient-specific 503A compounding against documented clinical need is not what is being decided.
Why it matters to what you pay
The compounded market survives in two lanes and this decision hits one. Of the 37 programs in our database, 17 describe a 503A arrangement explicitly and 8 name their compounding pharmacy at all. The rest say "partner pharmacies", which tells you nothing about which lane they are in — and after a final rule, that ambiguity becomes the thing you cannot afford.
What to do while it is undecided
Ask your program in writing which pharmacy fills your prescription and whether it is a 503A pharmacy or a 503B outsourcing facility. That single answer tells you your exposure. Weigh any prepaid twelve-month plan against the possibility that your program's supply lane changes inside the term.
If you are already on a compounded program, do not stop on the basis of a proposal that has not been finalised. Discontinuation has its own consequences and that is a conversation for your prescriber.
Verified . Regulatory positions, prices and trial results move — check the primary source before relying on a date. Compounded tirzepatide and semaglutide are not FDA-approved products.
Questions
Are compounded GLP-1s banned in 2026?
No. The FDA has proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. The comment period closed on 30 July 2026 and no final decision has been announced. Patient-specific 503A compounding against documented clinical need continues.
Were GLP-1s removed from the 503B bulks list?
They were never on it. The proposal would keep them off it, which forecloses a pathway rather than closing one that was open.
When will the FDA decide?
No date has been announced. The comment period closed on 30 July 2026 and the agency said it will consider comments before a final determination.